Métabolisme calcique

Nom du produit

Fibroblast Growth Factor 23 (C-terminal)

cFGF23

Cat. noBI-20702
Gamme0 – 20 pmol/l
Sensibilité0.1 pmol/l (STD2 0.2 pmol/l)
Durée d'incubationover night / 1 h / 30 min
Volume échantillon50 μl
Echantillon

Serum, EDTA/Heparin/Citrate plasma

Précautions

Centrifuge freshly collected blood as soon as possible
Store centrifuged samples at -20°C for longer storage.
Samples are stable up to 4 freeze and thaw cycles.
Hemolyzed or lipemic samples may cause erroneous results.

Valeurs de référence

Median serum (n=35): 0.8 pmol/l
Median EDTA plasma (n=22): 1.3 pmol/l
Median heparin plasma (n=22): 1.2 pmol/l
Median citrate plasma (n=30): 1.4 pmol/l

Espèces

Human

Tests96
MéthodeELISA
Intérêt clinique

Intended use:

FGF23 (fibroblast growth factor 23) is a member of the fibroblast growth factor family and controls phosphate and vitamin D homeostasis. The full-length protein comprises 251 amino acids including a 24 amino acid signal peptide. The N-terminal FGF homology region of FGF23 is separated from the unique C-terminal region by a proteolytic cleavage site. A proportion of FG23 is proteolytically processed between arginine179 and serine180 to generate N-terminal and C-terminal fragments. Therefore, the major forms of FGF23 present in human circulation are hormonally intact FGF23 and inactive N-terminal and C-terminal fragments. FGF23 binds to FGF receptor 1c (FGFR1c) with its N-terminal region, while the C-terminal region is capable of interacting with the co-receptor αKlotho to confer high-affinity binding to the receptor. FGFR1c and αKlotho are expressed in the distal nephron and the parathyroid gland. Co-receptor independent signaling of FGF23 has been described or other FGFRs, which are expressed in a variety of tissues. The main source of FGF23 are osteocytes in the
bone.

Intended applications:

  • Bone diseases
  • Cancer
  • Cardiovascular diseases
  • Endocrine disorders
  • Metabolic disorders
  • Kidney diseases
Informations utiles

Retour à l'index